Clinical Trial Update: Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

This Phase 2 trial provides long-term safety data for ATN-103 in rheumatoid arthritis patients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ATN-103

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED